Patent
Clinical diagnosis of hepatic fibrosis using a novel panel of human serum protein biomarkers
- Documentation:
- The inventors have proposed a novel panel of human serum protein biomarkers for diagnosing hepatic fibrosis and cirrhosis. Presently there is no reliable non-invasive way of assessing liver fibrosis. A 2D-P AGE based proteomics study was used to identify potential fibrosis biomarkers. Serum from patients with varying degrees of hepatic scarring induced by infection with the hepatitis C virus (HCV) was analysed. Several proteins associated with liver scarring and/or viral infection were identified. These proteins include the inter-α-trypsin inhibitor heavy chain H4 fragments, complement factor H-related protein 1, CD5L, Apo Ll, and β2GPI. Increased and decreased thiolester cleavage of a2M and Complement C3, respectively, was also detected. The concentrations of these novel biomarkers can be determined using an immunoassay where the concentrations would reflect the extent of fibrosis. A fibrosis scoring scale for each of the novel biomarkers is proposed. The additive result from the scores of all the novel biomarkers would give a more reliable indication of the degree of fibrosis rather than examining individual biomarkers.
- Publication status:
- Published
- Peer review status:
- Not peer reviewed
Actions
Authors
- Publisher:
- World Intellectual Property Organization
- Journal:
- World Intellectual Property Organization More from this journal
- Publication date:
- 2008-03-13
- Patent number:
-
WO/2008/031051
- Patent status:
- Issued/granted
- Pubs id:
-
pubs:383415
- UUID:
-
uuid:f7d39c64-5f6e-4384-91af-ee8a26e6224e
- Local pid:
-
pubs:383415
- Source identifiers:
-
383415
- Deposit date:
-
2016-02-04
- ARK identifier:
Terms of use
- Copyright date:
- 2008
If you are the owner of this record, you can report an update to it here: Report update to this record